October 14, 2015 | Israeli bio-medical company, Medgenics closed its secondary share offering, raising $46 million. The Galilee-based company opted to issue more shares after its share price climbed over 50% between January and September of this year. Currently, the company’s market capitalization is $236 million. Founded in 2000 and led by CEO Michael Cola, Medgenics is developing a technology platform called TARGT that will help to treat patients with rare and orphan diseases.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023

Israeli Startups Raise $1.6B in Q3, Indicating Stabilization - Report
September 27, 2023

Global Chip Maker Buying Renewable Energy From Israeli Firm
September 27, 2023

VC Fund Raises $480M For Cybersecurity Investment
September 26, 2023
Facebook comments